SAN DIEGO , June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib - Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium , May 22, 2018 (GLOBE NEWSWIRE) -- OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of tipifarnib in solid tumor and hematologic indications anticipated in second half of 2018 – – Company expects
SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd Annual Health Care Conference .
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for broader strategy to provide commercial exclusivity based upon biomarker-guided development – –
SAN DIEGO , May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial results after the close of U.S.
SAN DIEGO , April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK
SAN DIEGO , March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual Healthcare Conference.
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59 recurrent or metastatic HRAS mutant HNSCC patients with response rate as primary endpoint – – Company expects
SAN DIEGO , March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Cowen and Company 38th Annual Health Care Conference .
